<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580031</url>
  </required_header>
  <id_info>
    <org_study_id>Ayman HCG</org_study_id>
    <nct_id>NCT03580031</nct_id>
  </id_info>
  <brief_title>Booster Dose of HCG for Unruptured Follicle in Non IVF/ICSI Cycles</brief_title>
  <official_title>Booster Dose of Human Chorionic Gonadotrophin for Unruptured Follicle in Non IVF/ICSI Cycles: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to assess the effect of booster dose of hCG on the unruptured
      follicles in non IVF/ICSI cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study enrolled patients (n=160) who underwent controlled ovarian stimulation and
      timed intercourse with unruptured mature graffian follicle 48 hours after IM 10,000 IU HCG
      dose. Patients were allocated randomly into intervention group and control group. In the
      intervention group another booster dose (10,000 IU of hCG) was given IM while in the control
      group 2 ml normal saline was given IM leaving follicles for spontaneous rupture
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohort groups with parallel allocation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>48 hours</time_frame>
    <description>rupture of dominant follicle manifested by disappearance of follicle and presence of free fluid in douglas pouch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>15 days</time_frame>
    <description>Number of cases with positive serum pregnancy test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>LUF - Luteinised Unruptured Follicle Syndrome</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCG IM 10,000 IU Im 48 hours after first triggering dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 2m Injection im 48 hours after the first triggering dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <description>2 ml of normal saline will be injected 48 hours after first triggering dose</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ordinary stimulated cycles

          -  IUI stimulated cycles

          -  Unruptured follicle after 10000 IU IM HCG triggering

        Exclusion Criteria:

          -  IVF/ICSI cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman Dawood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer at Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman Dawood, MD</last_name>
    <phone>+201020972067</phone>
    <email>ayman.dawood@med.tanta.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adel Elgergawy, MD</last_name>
    <phone>+201002057250</phone>
    <email>dradelali775@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ayman Shehata Dawood</name>
      <address>
        <city>Tanta</city>
        <state>Algharbia</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Elhalwagy, MD</last_name>
      <phone>01202224924</phone>
      <phone_ext>002</phone_ext>
      <email>halwagy22@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ayman Dawood, MD</last_name>
      <phone>01020972067</phone>
      <phone_ext>002</phone_ext>
      <email>ayman.dawood@med.tanta.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>January 12, 2020</last_update_submitted>
  <last_update_submitted_qc>January 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Ayman S Dawood, MD</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>LUF</keyword>
  <keyword>HCG</keyword>
  <keyword>Booster dose</keyword>
  <keyword>Ovulation rate</keyword>
  <keyword>pregnancy rate</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be displayed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

